序号 |
标题 |
次数 |
作者 |
发布时间 |
75646 |
perfluorophenyl 1-(1,3-dioxoisoindolin-2-yloxy)-3,6,9,12-tetraoxapentadecan-15-oate |
109 |
wyh |
2024-12-19 |
75647 |
cas:2055041-37-5,Mal-PEG1-Val-Cit-PAB-OH,马来酰亚胺-一聚乙二醇-VAL-CIT-PAB-羟基 |
109 |
kx |
2024-12-19 |
75648 |
perfluorophenyl 15-(2,5-dioxo-2H-pyrrol-1(5H)-yl)-13-oxo-3,6,9-trioxa-12-azapentadecan-1-oate |
96 |
wyh |
2024-12-19 |
75649 |
MC-Val-Cit-PAB-PNP cas:159857-81-5 |
99 |
zyl |
2024-12-19 |
75650 |
NAMPT-linker(CAS号:2241019-57-6) |
83 |
WYQ |
2024-12-19 |
75651 |
cas:103848-61-9,6-Maleimidocaproic acid sulfo-NHS |
97 |
wyh |
2024-12-19 |
75652 |
cas:159857-80-4 ,MC-Val-Cit-PAB-OH, ADC(抗体偶联药物 ) |
102 |
kx |
2024-12-19 |
75653 |
Boc-Val-Cit cas:870487-08-4 |
128 |
zyl |
2024-12-19 |
75654 |
cas:663598-66-1,1-((4-((5-Nitropyridin-2-yl)disulfanyl)pentanoyl)oxy)-2,5-dioxopyrrolidine-3-sulfonic acid |
90 |
wyh |
2024-12-19 |
75655 |
cas:870487-10-8,Boc-Val-Cit-PAB-PNP,BOC-VAL-CIT-PAB-PNP 酯 |
93 |
kx |
2024-12-19 |
75656 |
cas:2353409-69-3 Mal-PEG8-Val-Cit-PAB-MMAE |
139 |
zyl |
2024-12-19 |
75657 |
cas:108852-90-0 Nemorubicin 奈莫柔比星 |
115 |
zyl |
2024-12-19 |
75658 |
cas:159858-22-7 , Fmoc-Val-Cit-PAB-OH,ADC(抗体偶联药物) |
78 |
kx |
2024-12-19 |
75659 |
cas:1626359-59-8 磺基-SPDB-DM4 |
82 |
zyl |
2024-12-19 |
75660 |
cas:870487-09-5,Boc-Val-Cit-PAB, ADC试剂 |
75 |
kx |
2024-12-19 |
75661 |
NH2-Glu-Gly-Cit-PAB-OH, ADC试剂 |
145 |
kx |
2024-12-19 |
75662 |
sulfo-SPDB-DGN462,用于提高化合物的水溶性和稳定性 |
133 |
WYQ |
2024-12-19 |
75663 |
Fmoc-Gly-Gly-Phe-Gly-OH, ADC试剂 |
108 |
kx |
2024-12-19 |
75664 |
1342211-31-7,MC-Val-Ala-OH,马来酰亚胺基己酰-L-缬氨酰-L-丙氨酸,ADC连接子多肽 |
140 |
kx |
2024-12-19 |
75665 |
MA-PEG4-VC-PAB-DMAE-PNU159682(CAS号:2259318-52-8) |
101 |
WYQ |
2024-12-19 |
75666 |
MC-vc-PAB-C6-a-amanitin,一种抗体药物偶联物(ADC) |
100 |
WYQ |
2024-12-19 |
75667 |
cas:690632-55-4,N-Succinimidyloxycarbonylpropyl Methanethiosulfonate |
64 |
wyh |
2024-12-19 |
75668 |
VC-MMAF(CAS号:863971-17-9) |
92 |
WYQ |
2024-12-19 |
75669 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin-ADC抗体偶联药物 |
83 |
zyl |
2024-12-19 |
75670 |
2055024-62-7,NH2-PEG3-Val-Cit-PAB-OH, ADC试剂 |
86 |
kx |
2024-12-19 |
75671 |
cas:1834516-06-1 Fmoc-Ala-Ala-Asn-PABC-PNP |
97 |
zyl |
2024-12-19 |
75672 |
perfluorophenyl 1-(1,3-dioxoisoindolin-2-yloxy)-3,6,9,12-tetraoxapentadecan-15-oate |
102 |
wyh |
2024-12-19 |
75673 |
MC -Val-Cit, ADC试剂 |
132 |
kx |
2024-12-19 |
75674 |
cas:141534-26-1,2-(4-formylbenzamido)ethyl nitrate |
146 |
wyh |
2024-12-19 |
75675 |
cas:159857-81-5 Mc-Val-Cit-PABC-PNP |
101 |
zyl |
2024-12-19 |
75676 |
MC-PEG4-va-PAB-Exatecan, ADC试剂 |
157 |
kx |
2024-12-19 |
75677 |
cas:2101206-44-2 PY-DS-DMBUT-OPFP |
120 |
zyl |
2024-12-19 |
75678 |
Perfluorophenyl 3-(2-(2-(4-formylbenzamido)ethoxy)ethoxy)propanoate |
59 |
wyh |
2024-12-19 |
75679 |
SMCC-DM4(CAS号:1228105-52-9) |
89 |
WYQ |
2024-12-19 |
75680 |
NHS ester-PEG4-VC-PAB-Dxd, ADC试剂 |
219 |
kx |
2024-12-19 |
75681 |
cas:53053-08-0,4-azidobenzoic acid N-hydroxysuccinimide ester |
69 |
wyh |
2024-12-19 |
75682 |
N3-Linker-Gefitinib,Gefitinib本身具有抗肿瘤活性 |
103 |
WYQ |
2024-12-19 |
75683 |
Boc-Val-Cit-OH的介绍 |
98 |
zyl |
2024-12-19 |
75684 |
mDPR-Val-Ala-PAB-MMAE, ADC试剂 |
116 |
kx |
2024-12-19 |
75685 |
Boc-Val-Ala-PAB-OC2H5 | ADC Linker |
104 |
zyl |
2024-12-19 |
75686 |
cas:2259318-56-2,DBCO-PEG4-VC-PAB-DMAE-PNU159682, ADC试剂 |
106 |
kx |
2024-12-19 |
75687 |
Mc-Dexamethasone,CAS号:1618096-56-2 |
115 |
WYQ |
2024-12-19 |
75688 |
N3-PEG4-YPYDVPDYA-Doxorubicin,抗体偶联药物(ADC)的一部分 |
143 |
WYQ |
2024-12-19 |
75689 |
DBCO-PEG4-VA-PAB-EDA-N-Ac-Calicheamicin,ADC定制 |
144 |
kx |
2024-12-19 |
75690 |
N3-PEG4-DYKDDDD-Doxorubicin,抗体偶联药物(ADC)的一部分 |
125 |
WYQ |
2024-12-19 |